Latest Headlines

Latest Headlines

Crucell investor agitates for more from J&J;

A key Crucell shareholder is revolting against Johnson & Johnson's buyout bid. Van Herk Groep, which owns 10 percent of Crucell, is urging the company's board to revoke its support for J&J;'s

J&J; hopes to boost vax business with Crucell buy

The world's largest diversified healthcare group Johnson & Johnson said Wednesday it will buy Dutch biotechnology firm Crucell for €1.75 billion ($2.4 billion)--a move that will help it

For J&J;, Crucell ops quality an acquisition bonus

Drug giant Johnson & Johnson says it intends to maintain the existing facilities of Crucell, which it has reached an agreement to acquire, and make them the center for vaccines within the Johnson

Investors buck as Crucell backs J&J;'s $2.4B bid

Crucell is throwing its support behind J&J;'s unchanged $2.4 billion bid to acquire control of the European biotech, despite the restiveness of some big investors who would like to see more money

J&J; agrees to buy Crucell for $2.4B

Johnson & Johnson announced this morning that it has reached a deal to buy all outstanding equity of Dutch vaccines maker Crucell that it does not already own for approximately €1.75 billion

J&J; aims to build vaccines biz around Crucell

While Johnson & Johnson fights fires within its consumer drugs unit, it's looking to branch into the vaccines business. J&J; says it's close to reaching a deal for Crucell, the Dutch vaccines

Crucell eagerly accepts $2.3B buyout offer from J&J;

A year after buying a big chunk of Dutch biotech Crucell, J&J; is coming back to the table with $2.3 billion to buy out the company and absorb its vaccine and drug development programs. For

Crucell forges ahead with combo AIDS vax trial

Joining with a host of collaborators, Crucell plans to take a promising combo approach for a new AIDS vaccine into the clinic in the U.S. in an ambitious effort to forge ahead on one of the most

Crucell decides to tackle universal RSV vaccine project

When Johnson & Johnson handed over €302 million for an 18 percent stake in Crucell last year, the two companies signed off on an ambitious new vaccines venture, with the Dutch biotech

Studies show need for TB research

Standardizing the approach to tuberculosis diagnosis and treatment that is recommended by the World Health Organization allowed more than 36 million people to be cured between 1995 and 2008, averting